Health ❯ Healthcare ❯ Clinical Trials

Drug Development

Eli Lilly Combination Therapy Phase 3 Trials Targeted Therapy Alzheimer's Treatments Phase III Trials FDA Approval Antibody-Drug Conjugates Patient Outcomes Oral Medications

Sanofi’s Efdoralprin Alfa Beats Standard Therapy in Phase 2 AATD Trial

The recombinant design signals a possible plasma-free option that could ease weekly treatment burdens.

FDA Approves AstraZeneca’s Baxfendy for Hard-to-Control Hypertension

FDA Approves Bizengri for NRG1 Fusion-Positive Cholangiocarcinoma

NEJM Study and FDA Access Advance Daraxonrasib for Pancreatic Cancer

Avalo Therapeutics Reports Positive Phase 2 HS Results, Prices $375 Million Offering

FDA Authorizes Early Access to Daraxonrasib for Pancreatic Cancer Patients

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy

Pfizer’s Elrexfio Posts Phase 3 PFS Win Over Standard Multiple Myeloma Regimen

KRAS Pill Doubles Survival in Trial as Pancreatic Cancer Vaccine Advances

FDA Clears Dupixent as First Biologic for Young Children With Chronic Spontaneous Urticaria

EMA Validates Astellas Bid to Add Padcev–Keytruda Combo for Perioperative Muscle-Invasive Bladder Cancer

Zoldonrasib Shows Promising Early Efficacy in KRAS G12D Lung Cancer

Kailera Leaps 62% in Nasdaq Debut After $625 Million IPO

Experimental Pill Doubles Survival in Advanced Pancreatic Cancer Trial

Experimental Drug Elraglusib Extends Survival in Phase 2 Pancreatic Cancer Trial

Revolution Medicines Drug Nearly Doubles Survival in Phase 3 Pancreatic Cancer Trial

Mouse Study Finds Semaglutide Directly Reprograms Liver Cells to Ease Disease Without Weight Loss

New Study Explains Why BET Drugs Falter by Splitting BRD2 and BRD4 Roles

India’s Generic Semaglutide Wave Eats Into Mounjaro’s Lead as Novo Holds Share

NEJM Publication Confirms Phase 3 Win for Brepocitinib in Dermatomyositis